Neos Therapeutics (NEOS) Posts Wider-than-Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Neos Therapeutics Announces Second Quarter 2015 Financial Results
September 3, 2015 7:00 AM EDT- Company appoints Beth Hecht to Board of Directors -
- Conference call scheduled for 8:30 a.m. ET today -
DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)-- Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company with a latestage pipeline of innovative extended-release (XR) product candidates for the treatment of attention deficit hyperactivity disorder (ADHD), today announced financial results for the second quarter ended June 30, 2015. The Company also announced the appointment of Beth Hecht to its Board of Directors.
Recent Highlights
... More